Vosevi is aimed at tough to treat patients.
US authorities suspicious over marketing, rebates and payment support programmes.
Former health secretary says scandal was “criminal” cover-up.
Trial backs patient-friendly regime in tough to treat strain.
Company needs to make acquisition to grow, admits CEO.
Company’s Eric Hughes on what it takes to be leader in NASH – and what can be learnt from hepatitis C.
Companies aim to cut treatment time and side effects.
Examining the views of different stakeholders in the ecosystem supporting drug R&D.